U.S. Food and Drug Administration has granted final approval for the Teva Pharmaceutical Industries Ltd 's Abbreviated New Drug Application (ANDA) to market its generic version of Pfizer's chemotherapy agent, Camptosar® (Irinotecan Hydrochloride) Injection, 20 mg/mL.

Teva Pharmaceutical Industries Ltd will market its generic version of Pfizer's chemotherapy agent, Camptosar® (Irinotecan Hydrochloride) Injection, 20 mg/mL. This product is available in 40 mg/2 mL and 100 mg/5 mL single dose vials.

The brand product had annual sales of approximately $556 million in the United States for the twelve months that ended December 31, 2007, based on IMS sales data.

Teva Pharmaceutical Industries Ltd develops, manufactures and markets generic and innovative human pharmaceuticals and active pharmaceutical ingredients. Over 80 percent of Teva's sales are in North America and Europe.